{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "NCT02652130",
            "NStudiesAvail": 430269,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "EventGroupOtherNumAtRisk",
                  "EventGroupSeriousNumAffected",
                  "EventGroupSeriousNumAtRisk",
                  "EventGroupTitle",
                  "EventsDescription",
                  "EventsFrequencyThreshold",
                  "EventsTimeFrame",
                  "ExpAccTypeIndividual",
                  "ExpAccTypeIntermediate",
                  "ExpAccTypeTreatment",
                  "ExpandedAccessNCTId",
                  "ExpandedAccessStatusForNCTId",
                  "FDAAA801Violation",
                  "FlowAchievementComment",
                  "FlowAchievementGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "EventGroupOtherNumAtRisk": [
                              "32"
                        ],
                        "EventGroupSeriousNumAffected": [
                              "15"
                        ],
                        "EventGroupSeriousNumAtRisk": [
                              "32"
                        ],
                        "EventGroupTitle": [
                              "Remestemcel-L"
                        ],
                        "EventsDescription": [
                              "Safety population included all participants who signed the informed consent form and received at least one dose of study treatment (complete or partial) in Study MSB-GVHD001 and who signed the informed consent form for Study MSB-GVHD002. As no treatment was administered in this study, only serious adverse events are reported. Any non-serious treatment-emergent adverse events that occurred within 30 days of last treatment at the 5% threshold will be reported in Study MSB-GVHD001 [NCT02336230]."
                        ],
                        "EventsFrequencyThreshold": [
                              "5"
                        ],
                        "EventsTimeFrame": [
                              "Baseline (Day 100) up to Day 180 in Study MSB-GVHD002"
                        ],
                        "ExpAccTypeIndividual": [],
                        "ExpAccTypeIntermediate": [],
                        "ExpAccTypeTreatment": [],
                        "ExpandedAccessNCTId": [],
                        "ExpandedAccessStatusForNCTId": [],
                        "FDAAA801Violation": [],
                        "FlowAchievementComment": [],
                        "FlowAchievementGroupId": [
                              "FG000",
                              "FG000",
                              "FG000"
                        ],
                        "NCTId": [
                              "NCT02652130"
                        ]
                  }
            ]
      }
}